TY - JOUR
T1 - The role of cyclooxygenase inhibitors in cancer prevention
AU - Anderson, William F.
AU - Umar, Asad
AU - Viner, Jaye L.
AU - Hawk, Ernest T.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2002
Y1 - 2002
N2 - Carcinogenesis results from the long-term accumulation of genetic and epigenetic aberrations at the molecular level, which are under constant selection pressure for growth advantage. Recognizing that cancer is the result of this long-term, multi-step process provides opportunities for molecularly targeted cancer prevention. Ideally, chemopreventive agents should be low in toxicity, morbidity, and cost. Several individual agents and agent combinations are currently under evaluation in the U.S. National Cancer Institute's (NCI) chemoprevention agent development program. Nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) -1 and -2 are among the most promising classes of agents for targeted molecular prevention.
AB - Carcinogenesis results from the long-term accumulation of genetic and epigenetic aberrations at the molecular level, which are under constant selection pressure for growth advantage. Recognizing that cancer is the result of this long-term, multi-step process provides opportunities for molecularly targeted cancer prevention. Ideally, chemopreventive agents should be low in toxicity, morbidity, and cost. Several individual agents and agent combinations are currently under evaluation in the U.S. National Cancer Institute's (NCI) chemoprevention agent development program. Nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) -1 and -2 are among the most promising classes of agents for targeted molecular prevention.
UR - http://www.scopus.com/inward/record.url?scp=0036261051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036261051&partnerID=8YFLogxK
U2 - 10.2174/1381612023394935
DO - 10.2174/1381612023394935
M3 - Review article
C2 - 11945150
AN - SCOPUS:0036261051
SN - 1381-6128
VL - 8
SP - 1035
EP - 1062
JO - Current pharmaceutical design
JF - Current pharmaceutical design
IS - 12
ER -